Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV2C2
- Development stage
- Unknown
- Lead developer
- MimiVax
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
MV2C2 is a humanized monoclonal antibody and camelid single-domain antibody (sdAb) targeting survivin (BIRC5), an anti-apoptotic protein that is highly expressed in various cancers and involved in the survival of autoreactive immune cells. Developed by MimiVax, MV2C2 is designed to inhibit the function of survivin, thereby inducing apoptosis in malignant cells and potentially modulating immune responses in autoimmune diseases. The drug is currently in early-stage clinical development for autoimmune conditions and is undergoing IND-enabling studies for oncology indications, representing a novel approach to targeting intracellular proteins through antibody-based modalities.
- Other names
- MV2C2 AntibodyMV-2C2 AntibodyMV 2C2 Antibody
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on MV2C2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV2C2.